Perioperative use of recombinant activated factor VII in a Jehovah's Witness patient undergoing sigmoid colectomy
نویسندگان
چکیده
منابع مشابه
Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma.
Inherited factor VII (FVII) deficiency is a rare autosomal-recessive bleeding disorder. There are no clear guidelines regarding therapy in such patients when intracerebral surgery is performed. We report the use of recombinant activated FVII (rFVIIa) for the prophylaxis of bleeding in a female with FVII deficiency (8% of activity) undergoing urgent removal of a right fronto-rolandic intracerebr...
متن کاملUse of recombinant activated factor VII in trauma
In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety data. Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conduct...
متن کاملAnesthetic management of a patient with factor VII deficiency undergoing laparoscopic colectomy: a case report
Background Congenital factor VII (FVII) deficiency is a rare autosomal recessive coagulation disorder that is characterized by prolongation of prothrombin time. Recombinant activated FVII (rFVIIa) is widely used in the management of bleeding in patients with congenital FVII deficiency. We experienced anesthetic management of a patient with congenital FVII deficiency who was scheduled for laparo...
متن کاملUse of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report.
Planned surgical procedures at patients who refuse allogenic blood transfusion because of religious convictions are important problem, not only medical but also ethical and juristical. At the study authors report the successful use of activated recombinant factor VII (rFVIIa) for the reduction of perioperative blood loss in four years old child - Jehovah's Witness, who had planned Torode kyphec...
متن کاملOff-Label Use of Recombinant Activated Factor VII (NovoSeven®)
NovoSeven® (Novo Nordisk, Denmark) is a recombinant DNA preparation of activated blood coagulation factor VII (rFVIIa). It is used to manage bleeding in hemophilia patients for whom standard therapy is inadequate because of the presence of inhibitors to either factor VIII (hemophilia A) or factor IX (hemophilia B). It poses no risk for the transmission of human pathogens, and it is infused in r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Transfusion Alternatives in Transfusion Medicine
سال: 2006
ISSN: 1295-9022,1778-428X
DOI: 10.1111/j.1778-428x.2006.00003.x